Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease

Sang Hyoung Park, Hyo Jong Kim, Chang Kyun Lee, Eun Mi Song, Sang Bum Kang, Byung Ik Jang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Eun Young Kim, Yun Jin Jung, Soo Kyung Park, Dong Il Park, Byong Duk Ye, Sung Ae Jung, Suk Kyun Yang

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Backgrounds and Aims: We aimed to evaluate the safety of Bacille Calmette-Guérin [BCG] vaccination in infants born to mothers receiving anti-tumour necrosis factor [anti-TNF] therapy for inflammatory bowel disease. Methods: Adverse events of BCG vaccination were evaluated in 90 infants who were last exposed to anti-TNF agents at a median of gestational week 30. Results: After receiving BCG vaccination at a median age of 6 months [range, 0.25-11 months], three infants [3.3%] showed injection site swelling, two of whom also showed axillar lymphadenopathy. The rates of adverse events were similar between infants who were last exposed to anti-TNF agents before the third trimester [n = 35] and those who were last exposed in the third trimester [n = 55] [2.9% vs 3.6%; p = 1.00]. All adverse events were spontaneously resolved and there were no serious adverse events such as active tuberculosis infection or death. Conclusions: BCG vaccination after 6 months of age is of low risk in infants exposed to anti-TNF agents in utero.

Original languageEnglish
Pages (from-to)1780-1784
Number of pages5
JournalJournal of Crohn's and Colitis
Volume14
Issue number12
DOIs
StatePublished - 1 Dec 2021

Keywords

  • BCG
  • Inflammatory bowel disease
  • anti-tumor necrosis factor
  • infant

Fingerprint

Dive into the research topics of 'Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this